Shalby Share Price
122.15+0.00 (+0.21%)
-43.76% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
APOLLOHOSPNSE
MAXHEALTHNSE
MANIPALHOSNSE
ASTERDMNSE
FORTISNSE
MEDANTANSE
NHNSE
LALPATHLABNSE
KIMSNSE
AGARWALEYENSE
SHALBYNSE
Shalby Share Price
122.15+0.00 (+0.21%)
-43.76% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| 15% | 22% | 12% | 5% |
| 0% | -2% | -18% | 1706% |
| - | -3% | -27% | -44% |
| 6% | 5% | 4% | 3% |
Peer Comparison
Symbol
APOLLOHOSP
MAXHEALTH
MANIPALHOS
ASTERDM
FORTIS
MEDANTA
NH
LALPATHLAB
KIMS
AGARWALEYE
SHALBY
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 8,989 | ₹125737 Cr | 56.08 | 43.8 | 219.15 | ₹1942 Cr |
| 1,074.05 | ₹101061 Cr | 73.2 | 4.26 | 19.36 | ₹1442 Cr |
| 697.3 | ₹91656 Cr | 102.72 | 2.05 | 11.95 | ₹892 Cr |
| 744.6 | ₹64456 Cr | 136.94 | 3.01 | 9.46 | ₹388 Cr |
| 815.7 | ₹61061 Cr | 58.81 | 4.14 | 20.27 | ₹1042 Cr |
| 1,493.4 | ₹39740 Cr | 64.26 | 8.21 | 32.95 | ₹556 Cr |
| 1,911 | ₹38297 Cr | 44.59 | 14.73 | 71.14 | ₹806 Cr |
| 1,982 | ₹32935 Cr | 56.44 | 11.45 | 45.37 | ₹505 Cr |
| 776.8 | ₹32301 Cr | 152.07 | 1.79 | 14.23 | ₹241 Cr |
| 553.8 | ₹18439 Cr | 106.32 | 1.73 | 14.44 | ₹133 Cr |
| 121.28 | ₹1320 Cr | 33.68 | 0.77 | 10.46 | ₹37 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | Dec 2019 | Sep 2019 | Jun 2019 | Mar 2019 | Dec 2018 | Sep 2018 | Jun 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹313 Cr | ₹331 Cr | ₹287 Cr | ₹272 Cr | ₹285 Cr | ₹296 Cr | ₹265 Cr | ₹276 Cr | ₹268 Cr | ₹279 Cr | ₹244 Cr | ₹216 Cr | ₹238 Cr | ₹235 Cr | ₹199 Cr | ₹202 Cr | ₹202 Cr | ₹202 Cr | ₹163 Cr | ₹162 Cr | ₹182 Cr | ₹192 Cr | ₹145 Cr | ₹132 Cr | ₹116 Cr | ₹38 Cr | ₹109 Cr | ₹121 Cr | ₹126 Cr | ₹131 Cr | ₹113 Cr | ₹113 Cr | ₹119 Cr | ₹116 Cr |
| ₹5 Cr | ₹7 Cr | ₹8 Cr | ₹7 Cr | ₹4 Cr | ₹7 Cr | ₹5 Cr | ₹5 Cr | ₹7 Cr | ₹10 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹9 Cr | ₹4 Cr | ₹5 Cr | ₹4 Cr | ₹4 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹10 Cr | ₹2 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹3 Cr |
| ₹318 Cr | ₹339 Cr | ₹296 Cr | ₹279 Cr | ₹290 Cr | ₹303 Cr | ₹270 Cr | ₹281 Cr | ₹275 Cr | ₹289 Cr | ₹249 Cr | ₹221 Cr | ₹243 Cr | ₹240 Cr | ₹208 Cr | ₹207 Cr | ₹207 Cr | ₹206 Cr | ₹167 Cr | ₹165 Cr | ₹184 Cr | ₹195 Cr | ₹147 Cr | ₹134 Cr | ₹118 Cr | ₹41 Cr | ₹119 Cr | ₹123 Cr | ₹128 Cr | ₹134 Cr | ₹116 Cr | ₹115 Cr | ₹122 Cr | ₹119 Cr |
| ₹291 Cr | ₹308 Cr | ₹277 Cr | ₹259 Cr | ₹261 Cr | ₹271 Cr | ₹260 Cr | ₹258 Cr | ₹252 Cr | ₹250 Cr | ₹221 Cr | ₹186 Cr | ₹198 Cr | ₹204 Cr | ₹186 Cr | ₹180 Cr | ₹177 Cr | ₹173 Cr | ₹150 Cr | ₹145 Cr | ₹164 Cr | ₹163 Cr | ₹123 Cr | ₹110 Cr | ₹95 Cr | ₹52 Cr | ₹115 Cr | ₹108 Cr | ₹107 Cr | ₹111 Cr | ₹106 Cr | ₹102 Cr | ₹105 Cr | ₹100 Cr |
| ₹46 Cr | ₹49 Cr | ₹37 Cr | ₹37 Cr | ₹46 Cr | ₹49 Cr | ₹26 Cr | ₹39 Cr | ₹40 Cr | ₹55 Cr | ₹44 Cr | ₹47 Cr | ₹58 Cr | ₹48 Cr | ₹35 Cr | ₹38 Cr | ₹42 Cr | ₹44 Cr | ₹28 Cr | ₹31 Cr | ₹32 Cr | ₹41 Cr | ₹33 Cr | ₹33 Cr | ₹32 Cr | -₹3 Cr | ₹13 Cr | ₹24 Cr | ₹31 Cr | ₹32 Cr | ₹17 Cr | ₹22 Cr | ₹25 Cr | ₹27 Cr |
| ₹11 Cr | ₹11 Cr | ₹9 Cr | ₹11 Cr | ₹10 Cr | ₹9 Cr | ₹11 Cr | ₹11 Cr | ₹9 Cr | ₹8 Cr | ₹6 Cr | ₹4 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹99 L | ₹76 L | ₹90 L | ₹78 L | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹2 Cr | ₹1 Cr |
| ₹16 Cr | ₹20 Cr | ₹10 Cr | ₹9 Cr | ₹19 Cr | ₹23 Cr | -₹74 L | ₹12 Cr | ₹14 Cr | ₹30 Cr | ₹22 Cr | ₹31 Cr | ₹43 Cr | ₹33 Cr | ₹19 Cr | ₹24 Cr | ₹29 Cr | ₹31 Cr | ₹15 Cr | ₹14 Cr | ₹19 Cr | ₹31 Cr | ₹23 Cr | ₹23 Cr | ₹22 Cr | -₹13 Cr | ₹2 Cr | ₹14 Cr | ₹20 Cr | ₹21 Cr | ₹7 Cr | ₹12 Cr | ₹15 Cr | ₹18 Cr |
| ₹8 Cr | ₹10 Cr | ₹18 Cr | ₹1 Cr | ₹7 Cr | ₹8 Cr | -₹12 Cr | -₹3 Cr | ₹2 Cr | ₹15 Cr | ₹16 Cr | ₹19 Cr | ₹28 Cr | ₹21 Cr | ₹14 Cr | ₹15 Cr | ₹18 Cr | ₹20 Cr | ₹10 Cr | ₹13 Cr | ₹11 Cr | ₹20 Cr | ₹10 Cr | ₹17 Cr | ₹24 Cr | -₹9 Cr | -₹17 Cr | ₹8 Cr | ₹13 Cr | ₹24 Cr | ₹3 Cr | ₹13 Cr | ₹4 Cr | ₹12 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Revaluation reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹108 Cr | ₹107 Cr | ₹107 Cr | ₹107 Cr | ₹108 Cr | ₹108 Cr | ₹108 Cr | ₹108 Cr | ₹108 Cr | ₹87 Cr | ₹88 Cr | ₹35 Cr | ₹35 Cr | ₹35 Cr |
| ₹1 Cr | ₹1 Cr | ₹82 L | ₹82 L | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹27 L | ₹0 | ₹0 | ₹0 | ₹4 L |
| ₹897 Cr | ₹884 Cr | ₹892 Cr | ₹820 Cr | ₹768 Cr | ₹727 Cr | ₹691 Cr | ₹672 Cr | ₹643 Cr | ₹164 Cr | ₹117 Cr | ₹133 Cr | ₹105 Cr | ₹67 Cr |
| ₹897 Cr | ₹884 Cr | ₹892 Cr | ₹820 Cr | ₹768 Cr | ₹727 Cr | ₹691 Cr | ₹672 Cr | ₹643 Cr | ₹164 Cr | ₹117 Cr | ₹133 Cr | ₹105 Cr | ₹67 Cr |
| -₹70,000 | -₹70,000 | -₹70,000 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹1005 Cr | ₹992 Cr | ₹1000 Cr | ₹928 Cr | ₹876 Cr | ₹835 Cr | ₹799 Cr | ₹780 Cr | ₹751 Cr | ₹251 Cr | ₹205 Cr | ₹168 Cr | ₹141 Cr | ₹102 Cr |
| ₹46 L | ₹3 Cr | ₹7 Cr | -₹7 L | -₹14 L | ₹2 L | ₹5 L | ₹5 L | ₹6 L | -₹62 L | ₹37 L | ₹2 Cr | ₹3 Cr | ₹4 Cr |
| ₹153 Cr | ₹137 Cr | ₹176 Cr | ₹67 Cr | ₹87 Cr | ₹36 Cr | ₹49 Cr | ₹57 Cr | ₹75 Cr | ₹235 Cr | ₹151 Cr | ₹74 Cr | ₹23 Cr | ₹42 L |
| ₹0 | ₹0 | ₹13 L | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹50 Cr | ₹50 Cr | ₹0 | ₹0 | ₹0 |
| ₹49 Cr | ₹63 Cr | ₹35 Cr | ₹43 Cr | ₹31 Cr | ₹23 Cr | ₹18 Cr | -₹2 Cr | -₹11 Cr | -₹7 Cr | ₹2 Cr | ₹11 Cr | ₹3 Cr | -₹20 L |
| ₹49 Cr | ₹47 Cr | ₹61 Cr | ₹46 Cr | ₹24 Cr | ₹20 Cr | ₹16 Cr | ₹12 Cr | ₹18 Cr | ₹11 Cr | ₹3 Cr | ₹5 Cr | ₹7 Cr | ₹9 Cr |
| ₹71 Cr | ₹43 Cr | ₹116 Cr | ₹113 Cr | ₹92 Cr | ₹72 Cr | ₹62 Cr | ₹63 Cr | ₹58 Cr | ₹2 Cr | ₹90 L | ₹56 L | ₹41 L | ₹33 L |
| ₹321 Cr | ₹290 Cr | ₹388 Cr | ₹269 Cr | ₹234 Cr | ₹150 Cr | ₹144 Cr | ₹130 Cr | ₹140 Cr | ₹291 Cr | ₹207 Cr | ₹90 Cr | ₹33 Cr | ₹10 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹128 Cr | ₹118 Cr | ₹130 Cr | ₹88 Cr | ₹71 Cr | ₹58 Cr | ₹60 Cr | ₹56 Cr | ₹49 Cr | ₹39 Cr | ₹47 Cr | ₹61 Cr | ₹20 Cr | ₹20 Cr |
| ₹111 Cr | ₹93 Cr | ₹87 Cr | ₹56 Cr | ₹57 Cr | ₹24 Cr | ₹22 Cr | ₹31 Cr | ₹49 Cr | ₹63 Cr | ₹35 Cr | ₹21 Cr | ₹12 Cr | ₹13 Cr |
| ₹332 Cr | ₹241 Cr | ₹104 Cr | ₹49 Cr | ₹43 Cr | ₹0 | ₹0 | ₹0 | ₹16 Cr | ₹26 Cr | ₹9 Cr | ₹8 Cr | ₹8 Cr | ₹3 Cr |
| ₹4 Cr | ₹4 Cr | ₹3 Cr | ₹1 Cr | ₹1 Cr | ₹57 L | ₹73 L | ₹65 L | ₹25 Cr | ₹71 Cr | ₹17 L | ₹5 L | ₹11 L | ₹8 L |
| ₹576 Cr | ₹455 Cr | ₹323 Cr | ₹194 Cr | ₹172 Cr | ₹82 Cr | ₹83 Cr | ₹88 Cr | ₹138 Cr | ₹199 Cr | ₹92 Cr | ₹90 Cr | ₹40 Cr | ₹36 Cr |
| ₹1902 Cr | ₹1740 Cr | ₹1719 Cr | ₹1391 Cr | ₹1282 Cr | ₹1066 Cr | ₹1027 Cr | ₹998 Cr | ₹1030 Cr | ₹741 Cr | ₹504 Cr | ₹351 Cr | ₹217 Cr | ₹152 Cr |
| ₹19 Cr | ₹30 Cr | ₹17 Cr | ₹23 Cr | ₹88 Cr | ₹89 Cr | ₹78 Cr | ₹75 Cr | ₹22 Cr | ₹27 Cr | ₹23 Cr | ₹19 Cr | ₹5 Cr | ₹7 Cr |
| ₹540 Cr | ₹427 Cr | ₹314 Cr | ₹142 Cr | ₹155 Cr | ₹44 Cr | ₹62 Cr | ₹71 Cr | ₹114 Cr | ₹328 Cr | ₹224 Cr | ₹98 Cr | ₹37 Cr | ₹5 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹1482 Cr | ₹1329 Cr | ₹1285 Cr | ₹910 Cr | ₹860 Cr | ₹804 Cr | ₹782 Cr | ₹766 Cr | ₹691 Cr | ₹341 Cr | ₹428 Cr | ₹300 Cr | ₹232 Cr | ₹208 Cr |
| ₹436 Cr | ₹373 Cr | ₹319 Cr | ₹225 Cr | ₹185 Cr | ₹145 Cr | ₹110 Cr | ₹74 Cr | ₹41 Cr | ₹18 Cr | ₹109 Cr | ₹125 Cr | ₹102 Cr | ₹91 Cr |
| ₹1046 Cr | ₹955 Cr | ₹966 Cr | ₹685 Cr | ₹675 Cr | ₹660 Cr | ₹672 Cr | ₹692 Cr | ₹650 Cr | ₹323 Cr | ₹319 Cr | ₹175 Cr | ₹130 Cr | ₹117 Cr |
| ₹39 L | ₹8 Cr | ₹11 Cr | ₹6 Cr | ₹5 Cr | ₹4 Cr | ₹3 Cr | ₹2 Cr | ₹46 Cr | ₹221 Cr | ₹82 Cr | ₹91 Cr | ₹5 Cr | ₹2 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹11 L | ₹11 L | ₹11 L | ₹11 L | ₹11 L | ₹11 L | ₹11 L | ₹11 L | ₹11 L |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹11 L | ₹11 L | ₹11 L | ₹11 L | ₹11 L | ₹11 L | ₹11 L | ₹11 L | ₹11 L |
| ₹114 Cr | ₹92 Cr | ₹180 Cr | ₹176 Cr | ₹148 Cr | ₹121 Cr | ₹111 Cr | ₹102 Cr | ₹97 Cr | ₹38 Cr | ₹38 Cr | ₹22 Cr | ₹18 Cr | ₹6 Cr |
| ₹4 Cr | ₹13 Cr | ₹5 Cr | ₹3 Cr | ₹4 Cr | ₹8 Cr | ₹3 Cr | ₹4 Cr | ₹28 L | ₹27 L | ₹18 L | ₹33 L | ₹57 L | ₹24 L |
| ₹1183 Cr | ₹1082 Cr | ₹1167 Cr | ₹874 Cr | ₹833 Cr | ₹795 Cr | ₹793 Cr | ₹801 Cr | ₹794 Cr | ₹582 Cr | ₹440 Cr | ₹289 Cr | ₹154 Cr | ₹125 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹62 Cr | ₹95 Cr | ₹81 Cr | ₹146 Cr | ₹25 Cr | ₹16 Cr | ₹28 Cr | ₹11 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹9 L | ₹10 L |
| ₹376 Cr | ₹319 Cr | ₹235 Cr | ₹185 Cr | ₹121 Cr | ₹23 Cr | ₹15 Cr | ₹13 Cr | ₹12 Cr | ₹8 Cr | ₹7 Cr | ₹6 Cr | ₹6 Cr | ₹6 Cr |
| ₹228 Cr | ₹175 Cr | ₹145 Cr | ₹106 Cr | ₹101 Cr | ₹95 Cr | ₹95 Cr | ₹81 Cr | ₹51 Cr | ₹34 Cr | ₹31 Cr | ₹22 Cr | ₹15 Cr | ₹12 Cr |
| ₹22 Cr | ₹35 Cr | ₹27 Cr | ₹12 Cr | ₹111 Cr | ₹84 Cr | ₹29 Cr | ₹25 Cr | ₹116 Cr | ₹16 Cr | ₹16 Cr | ₹31 Cr | ₹12 Cr | ₹5 Cr |
| ₹5 Cr | ₹6 Cr | ₹9 Cr | ₹5 Cr | ₹15 Cr | ₹18 Cr | ₹15 Cr | ₹12 Cr | ₹16 Cr | ₹12 Cr | ₹80 L | ₹54 L | ₹66 L | ₹41 L |
| ₹25 Cr | ₹28 Cr | ₹55 Cr | ₹62 Cr | ₹70 Cr | ₹37 Cr | ₹52 Cr | ₹55 Cr | ₹41 Cr | ₹90 Cr | ₹8 Cr | ₹4 Cr | ₹29 Cr | ₹3 Cr |
| ₹719 Cr | ₹658 Cr | ₹552 Cr | ₹517 Cr | ₹442 Cr | ₹271 Cr | ₹234 Cr | ₹197 Cr | ₹236 Cr | ₹159 Cr | ₹64 Cr | ₹63 Cr | ₹63 Cr | ₹27 Cr |
| ₹144 Cr | ₹203 Cr | ₹229 Cr | ₹323 Cr | ₹270 Cr | ₹189 Cr | ₹150 Cr | ₹109 Cr | ₹97 Cr | -₹41 Cr | -₹28 Cr | -₹28 Cr | ₹23 Cr | -₹9 Cr |
| ₹1902 Cr | ₹1740 Cr | ₹1719 Cr | ₹1391 Cr | ₹1282 Cr | ₹1066 Cr | ₹1027 Cr | ₹998 Cr | ₹1030 Cr | ₹741 Cr | ₹504 Cr | ₹351 Cr | ₹217 Cr | ₹152 Cr |
| ₹93 | ₹92 | ₹93 | ₹86 | ₹81 | ₹77 | ₹74 | ₹72 | ₹70 | ₹29 | ₹23 | ₹48 | ₹40 | ₹29 |
| ₹93 | ₹92 | ₹93 | ₹86 | ₹81 | ₹77 | ₹74 | ₹72 | ₹70 | ₹29 | ₹23 | ₹19 | ₹16 | ₹12 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Cash & Cash Equivalent of Subsidiaries under liquidations
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹61 Cr | ₹56 Cr | ₹128 Cr | ₹102 Cr | ₹79 Cr | ₹55 Cr | ₹57 Cr | ₹50 Cr | ₹54 Cr | ₹50 Cr | ₹36 Cr | ₹43 Cr | ₹52 Cr | ₹19 Cr |
| ₹78 Cr | ₹85 Cr | ₹52 Cr | ₹40 Cr | ₹53 Cr | ₹38 Cr | ₹37 Cr | ₹36 Cr | ₹33 Cr | ₹26 Cr | ₹17 Cr | ₹26 Cr | ₹13 Cr | ₹28 Cr |
| -₹99 Cr | -₹131 Cr | -₹140 Cr | -₹46 Cr | -₹91 Cr | -₹4 Cr | -₹18 Cr | -₹33 Cr | -₹61 Cr | -₹6 Cr | -₹38 Cr | ₹66 Cr | -₹47 Cr | ₹57 Cr |
| ₹40 Cr | ₹10 Cr | ₹40 Cr | ₹96 Cr | ₹42 Cr | ₹88 Cr | ₹76 Cr | ₹53 Cr | ₹26 Cr | ₹71 Cr | ₹15 Cr | ₹135 Cr | ₹18 Cr | ₹105 Cr |
| -₹1 L | -₹4 Cr | ₹20 Cr | ₹68 Cr | ₹19 Cr | ₹79 Cr | ₹55 Cr | ₹43 Cr | ₹14 Cr | ₹60 Cr | ₹5 Cr | ₹123 Cr | ₹5 Cr | ₹95 Cr |
| -₹97 Cr | -₹36 Cr | ₹38 Cr | -₹61 Cr | -₹60 Cr | -₹51 Cr | -₹31 Cr | ₹1 Cr | -₹237 Cr | -₹153 Cr | -₹98 Cr | -₹62 Cr | -₹26 Cr | -₹9 Cr |
| ₹84 Cr | ₹48 Cr | -₹151 Cr | -₹50 Cr | ₹90 Cr | -₹30 Cr | -₹21 Cr | -₹51 Cr | ₹222 Cr | ₹96 Cr | ₹75 Cr | -₹39 Cr | ₹24 Cr | -₹86 Cr |
| -₹13 Cr | ₹8 Cr | -₹93 Cr | -₹43 Cr | ₹49 Cr | -₹2 Cr | ₹3 Cr | -₹6 Cr | -₹36 L | ₹3 Cr | -₹19 Cr | ₹22 Cr | ₹3 Cr | ₹32 L |
| ₹35 Cr | ₹27 Cr | ₹12 Cr | ₹56 Cr | ₹6 Cr | ₹8 Cr | ₹5 Cr | ₹12 Cr | ₹12 Cr | ₹9 Cr | ₹27 Cr | ₹6 Cr | ₹2 Cr | ₹2 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹37 L | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹0 | ₹0 | ₹108 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹22 Cr | ₹35 Cr | ₹27 Cr | ₹12 Cr | ₹56 Cr | ₹6 Cr | ₹8 Cr | ₹5 Cr | ₹12 Cr | ₹12 Cr | ₹9 Cr | ₹27 Cr | ₹6 Cr | ₹2 Cr |
Fundamental Ratios
Consolidated
Standalone

No results found
Shalby Share Price
122.15+0.00 (+0.21%)
-43.76% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 2
Bearish signals: 3 out of 9 oscillators
RSI
46.05Neutral
STOCH %K
35.20Neutral
MACD Level(12,26)
-2.16Sell
Ultimate Oscillator
39.10Sell
Aroon Oscillator
-60.00Sell
BOP
0.05Buy
CCI
-15.02Neutral
Williams %R
-64.80Neutral
Momentum
1.74Buy
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 3
Bearish signals: 6 out of 9 moving averages
EMA 9
121.90Buy
SMA 9
122.49Sell
EMA 21
123.19Sell
SMA 21
121.13Buy
EMA 50
130.22Sell
SMA 50
129.79Sell
EMA 200
154.25Sell
SMA 200
152.71Sell
WMA 20
122.00Buy
Pivot
Pivot
Classic
Resistance 5
142.26
Resistance 4
136.96
Resistance 3
131.66
Resistance 2
126.36
Resistance 1
124.13
Pivot
121.06
Support 1
118.83
Support 2
115.76
Support 3
110.46
Support 4
105.16
Support 5
99.86
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Shalby Share Price
122.15+0.00 (+0.21%)
-43.76% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| 74.33% | 74.33% | 74.33% | 74.33% | 74.33% | 74.27% |
| 4.65% | 4.47% | 4.36% | 4.47% | 4.63% | 5.21% |
| 0.29% | 0.29% | 0.25% | 0.19% | 0.19% | 0.19% |
| 0.02% | 0.01% | 0.00% | 0.00% | 0.00% | 0.00% |
| 20.71% | 20.90% | 21.06% | 21.01% | 20.85% | 20.33% |
Bulk & block deals
Name
Graviton Research Capital Llp
Graviton Research Capital Llp
Musigma Securities
Nk Securities Research Private Limited
Nk Securities Research Private Limited
Musigma Securities
First Water Fund
Haresh Tikamdas Kaswani
First Water Fund
Haresh Tikamdas Kaswani
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 22 Sep 2025 | Purchase | 36.07 Cr | ₹266.34 | 13.54 L | Bulk | 1.253687 | NSE |
| 22 Sep 2025 | Sell | 36.09 Cr | ₹266.55 | 13.54 L | Bulk | 1.253687 | NSE |
| 05 Sep 2025 | Purchase | 12.24 Cr | ₹223.24 | 5.48 L | Bulk | 0.507767 | NSE |
| 05 Sep 2025 | Purchase | 12.71 Cr | ₹223.40 | 5.69 L | Bulk | 0.526713 | NSE |
| 05 Sep 2025 | Sell | 12.72 Cr | ₹223.57 | 5.69 L | Bulk | 0.526713 | NSE |
| 05 Sep 2025 | Sell | 12.25 Cr | ₹223.36 | 5.48 L | Bulk | 0.507767 | NSE |
| 13 Jun 2025 | Purchase | 12.60 Cr | ₹180 | 7 L | Bulk | 0.648089 | NSE |
| 13 Jun 2025 | Sell | 12.60 Cr | ₹180 | 7 L | Bulk | 0.648089 | NSE |
| 13 Jun 2025 | Purchase | 12.60 Cr | ₹180 | 7 L | Block | 0.648089 | NSE |
| 13 Jun 2025 | Sell | 12.60 Cr | ₹180 | 7 L | Block | 0.648089 | NSE |
Insider trading & SAST
Client name
Vikram Indrajit Shah
Vikram Indrajit Shah
Shah Family Trust
Shah Family Trust Through Dr. Vikram I Shah, Trustee
Dr Vikram Shah
Dr. Vikram Indrajit Shah
Dr Vikram Indrajit Shah
Dr. Vikram Indrajit Shah
Dr Vikram Indrajit Shah
Vikram Indrajit Shah
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21 Nov 2026 | Promoter and Director | Acquisition | 0.009258 | 7.43 | 12.29 L | ₹122.91 | 10 K | 19 Nov 2026 | Market Purchase | 80,20,493 | Insider Trading | — | Equity |
| 21 Aug 2026 | Promoter and Director | Acquisition | 0.004629 | 7.42 | 7.74 L | ₹154.72 | 5 K | 19 Aug 2026 | Market Purchase | 80,10,493 | Insider Trading | — | Equity |
| 14 Oct 2025 | Promoter | Acquisition | 0.06 | 34.79 | 0 | — | 60 K | 19 Sep 2025 | Market | 3,75,77,132 | SAST | 29(2) | — |
| 20 Sep 2025 | Promoter | Acquisition | 0.055551 | 34.79 | 1.44 Cr | ₹240.18 | 60 K | 19 Sep 2025 | Market Purchase | 3,75,77,132 | Insider Trading | — | Equity Shares |
| 22 Nov 2024 | Promoter | Acquisition | 0.02 | 7.41 | 0 | — | 25 K | 14 Nov 2024 | Market | 80,05,493 | SAST | 29(2) | — |
| 15 Nov 2024 | Promoter & Director | Acquisition | 0.023146 | 7.41 | 54.55 L | ₹218.19 | 25 K | 14 Nov 2024 | Market Purchase | 80,05,493 | Insider Trading | — | Equity Shares |
| 27 Jun 2024 | Promoter | Acquisition | — | 7.39 | 0 | — | 10 K | 05 Jun 2024 | Market | 79,80,493 | SAST | 29(2) | — |
| 06 Jun 2024 | Promoter & Director | Acquisition | 0.009258 | 7.39 | 25.42 L | ₹254.16 | 10 K | 05 Jun 2024 | Market Purchase | 79,80,493 | Insider Trading | — | Equity Shares |
| 14 Mar 2024 | Promoter | Acquisition | 0.12 | 7.38 | 0 | — | 1.25 L | 06 Mar 2024 | Market | 79,70,493 | SAST | 29(2) | — |
| 07 Mar 2024 | Promoter & Director | Acquisition | 0.11573 | 7.38 | 3.05 Cr | ₹244.20 | 1.25 L | 06 Mar 2024 | Market Purchase | 79,70,493 | Insider Trading | — | Equity Shares |
Shalby Share Price
122.15+0.00 (+0.21%)
-43.76% past 1 Year
Shalby Hospitals ( Shalby Limited) established in 1994 in Ahmedabad Gujarat operates a chain of multispecialty hospitals across India holding an aggregate bed capacity of over 2000 hospital beds. Shalby’s
Corporate Actions
Date
Type
Details
Company details
Shalby Share Price
122.15+0.00 (+0.21%)
-43.76% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Shalby Share Price
122.15+0.00 (+0.21%)
-43.76% past 1 Year
News
1 of 20
ResultSHALBY3 Nov 2026
NULL
Shalby Reports Stable Q2 EBITDA Amid Year On Year Margin Compression
ResultSHALBY3 Nov 2026
Shalby reported Q2 EBITDA of Rs 41.40 crores, compared with Rs 41.60 crores in the corresponding year ago quarter, indicating a marginal year on year decline. EBITDA margin narrowed to 13.21% from 14.58%, reflecting operating margin pressure despite broadly stable EBITDA.
Revenue, PAT, sequential performance, and management commentary were not provided in the available update. The reported EBITDA outcome appears broadly in line with the prior year, while the lower margin indicates weaker operating efficiency. The company operates in the healthcare services industry.
The result is assessed as neutral with low market impact because EBITDA remained broadly stable, although the year on year margin contraction is a negative operating indicator.
Shalby Reports Marginal Year on Year Decline In Q2 Consolidated Net Profit
ResultSHALBY3 Nov 2026
Shalby reported Q2 consolidated net profit of Rs 8.30 crores, compared with Rs 8.38 crores in the corresponding quarter of the previous year, representing a 0.95 percent year on year decline. Revenue, EBITDA, operating margin, net margin, and sequential quarter comparison were not provided in the available update. The result indicates broadly stable profitability, with the marginal decline limiting the immediate earnings impact.
Shalby Reports Stronger Second Quarter Revenue Growth Year on Year
ResultSHALBY3 Nov 2026
Shalby reported second quarter revenue of Rs 313.00 crores, compared with Rs 285.00 crores in the corresponding period of the previous year, representing approximately 9.8 percent year on year growth. EBITDA, PAT, operating margin, net margin, sequential revenue change, and management commentary were not provided in the available update.
The reported revenue increase indicates higher operating scale for the healthcare company. However, the absence of profitability and margin data limits assessment of earnings quality and overall quarterly performance. The update reflects a routine company-specific result and does not indicate an index-level impact.
Shalby posts stronger Q4 EBITDA and margin improvement on yearly basis
ResultSHALBY27 May 2026
Shalby reported a healthy improvement in operating performance for the fourth quarter, with EBITDA rising to Rs 29.30 crores from Rs 20.90 crores on a year-on-year basis. This indicates a notable expansion in operating profitability in absolute terms, reflecting better cost management, operating leverage, or an improved business mix during the period. The strong EBITDA growth outpaces typical single-digit growth trends often seen in the hospital and healthcare services space, suggesting that the company has gained momentum in its core operations over the past year.
EBITDA margin for Q4 improved to 10.20 percent compared with 7.89 percent in the same quarter last year. This margin expansion of more than 200 basis points signals enhanced operational efficiency and better control over operating expenses relative to revenue. A higher EBITDA margin is particularly important for healthcare services players like Shalby, as it provides greater buffer to absorb fluctuations in input costs such as manpower, medical consumables, and other hospital operating expenses. The improved margin profile also contributes positively to cash generation and the company’s ability to fund future growth or capex.
The available information focuses on EBITDA and EBITDA margin and does not specify revenue, PAT, or quarter-on-quarter comparisons, nor does it provide any reference to street expectations or management guidance. There is also no information on the immediate stock price reaction or trading volumes. Nonetheless, from a pure operational standpoint, the double-digit growth in EBITDA and meaningful margin expansion on a year-on-year basis indicates a strengthening underlying business performance for the quarter under review.
Shalby posts Q4 turnaround with profit and double-digit revenue growth
ResultSHALBY27 May 2026
Shalby reported a strong turnaround in its Q4 financial performance, moving from a consolidated net loss to profit on the back of healthy revenue growth. Consolidated net profit for Q4 stood at Rs 18.30 crores, compared with a loss of Rs 11.00 crores in the same quarter last year, indicating a significant improvement in the company’s profitability profile on a year-on-year basis. This swing from loss to profit suggests better operating leverage, improved cost control, or a more favourable business mix during the quarter, although detailed margin data is not provided in the context.
On the top line, Shalby’s Q4 revenue came in at Rs 290.00 crores, up from Rs 260.00 crores on a year-on-year basis, reflecting steady growth in business volumes and realisations. The double-digit increase in revenue, coupled with the shift to positive net profit, points to a broadly improved operational performance compared with the previous year’s corresponding quarter. However, the context does not provide quarter-on-quarter comparisons, EBITDA, or margin metrics, so a granular assessment of operating efficiency or cost trends is not possible here.
Street expectations, management commentary, detailed segmental performance, and guidance are not available in the provided text, and there is no information on immediate stock price reaction or changes in investor positioning. Nevertheless, from a pure earnings standpoint, the combination of revenue growth and a sharp turnaround in bottom line from loss to profit is generally perceived as a constructive development for the equity narrative. Investors and analysts are likely to await further disclosures on sustainability of this performance, margin trajectory, and any strategic initiatives to gauge the medium-term impact on valuations and sentiment.
Shalby reports Profit after tax of 53.67 Crores, in the March 2026 quarter
ResultSHALBY27 May 2026
NULL
Shalby informs about board meeting
Stock NewsSHALBY11 May 2026
NULL
Shalby moves up as its Krishna unit gets approval for Kidney Transplant for 5 years
Stock NewsSHALBY13 Apr 2026
It enhances continuity of care by offering comprehensive pre-and post-transplant management under one roof
Shalby’s Krishna unit gets approval for Kidney Transplant for 5 years
Stock NewsSHALBY13 Apr 2026
It enhances continuity of care by offering comprehensive pre-and post-transplant management under one roof
Shalby Limited Issues Standby Letter of Credit Up to USD 1.33 Crores via IndusInd Bank.
Stock NewsSHALBY9 Apr 2026
Shalby Limited has issued a Standby Letter of Credit (SBLC) worth up to **USD 1.33 crores** through IndusInd Bank for its subsidiary, Shalby Advanced Technologies, Inc. This financial instrument serves as a guarantee for potential obligations of the US-based subsidiary.
The transaction involves no major financial impact expected on Shalby Limited, indicating it is a routine banking arrangement without significant effects on the company's balance sheet, earnings, leverage, or cash flows. Such SBLCs are typically used to support international operations, procurement, or trade commitments without immediate cash outflow unless drawn upon.
Shalby operates in the healthcare sector, focusing on orthopedic treatments and advanced medical technologies. This development aligns with supporting its overseas subsidiary's activities, potentially aiding expansion or operational needs in the US market, though the minimal financial commitment underscores limited materiality.
Shalby informs about scrutinizers report
Stock NewsSHALBY23 Mar 2026
NULL
Shalby informs about updates
Stock NewsSHALBY23 Mar 2026
NULL
Shalby inaugurates oncology department with advanced radiotherapy facilities in Surat
Stock NewsSHALBY9 Mar 2026
With the launch of these advanced services, the hospital is now equipped to provide integrated cancer care
Shalby Limited Opens New Oncology Department with Advanced Radiotherapy at Surat Hospital.
Stock NewsSHALBY9 Mar 2026
Shalby Limited has launched a new Oncology Department at Shalby Hospital in Surat, featuring advanced radiotherapy capabilities and offering comprehensive all-in-one cancer treatment solutions. This expansion enhances the hospital's existing multispecialty services, which include surgical oncology, medical oncology, radiation oncology, chemotherapy, and supportive care such as palliative services and oncology pharmacy.
The Surat facility, with a bed capacity of 243 beds, now strengthens Shalby Hospitals' position in onco-sciences alongside its centres of excellence in joint replacement, critical care, neuro sciences, and more. The new department integrates diagnostic imaging, tumor boards, and customized multi-modality therapies, potentially boosting patient volumes, revenue streams from high-margin cancer care, and market share in the growing oncology segment in India.
This capex initiative aligns with Shalby Limited's strategy to expand specialized tertiary care, which may positively influence earnings through increased occupancy and premium service offerings at the Surat location.
Shalby Limited's Gurugram Subsidiary PK Healthcare Secures NABH Accreditation Valid Until 2030.
Stock NewsSHALBY4 Mar 2026
Shalby Limited announced that its subsidiary PK Healthcare Private Limited, operating Shalby International Hospitals in Gurugram, has received NABH accreditation under 6th Edition Standards, valid until 2030. This accreditation, confirmed in an NSE filing dated March 3, 2026, recognizes excellence in patient safety protocols, clinical governance, risk management, and quality improvement.
The NABH framework emphasizes comprehensive healthcare quality management, including patient-centered care, evidence-based practices, infection control, transparency, and continuous improvement. PK Healthcare, acquired with an 87% stake in January 2024 to expand Shalby's network in North India, now strengthens its competitive position through compliance with national benchmarks.
This milestone enhances Shalby Limited's reputation across its 2,000+ bed network, supports healthcare expansion initiatives, and validates operational excellence in the competitive hospital sector. No specific financial quantum or immediate stock price impact detailed in the announcement.
Shalby Limited Discontinues SOCE Operations in Rajkot and Lucknow Due to Economic Unworkability.
Stock NewsSHALBY2 Mar 2026
Shalby Limited has discontinued its SOCE operations in Rajkot, effective January 31, 2026, and in Lucknow, effective February 15, 2026, citing economic unworkability. This decision was intimated pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Outpatient Department (OPD) services will continue to operate in both locations.
The closure pertains to franchisee units, with no specific financial quantum such as revenue contribution or cost savings disclosed in the announcement. It may impact the company's operational footprint and earnings from these sites, potentially affecting short-term revenue streams in the hospital segment. However, the persistence of OPD services mitigates complete cessation of activities. Recent Q3 FY26 results showed consolidated revenue of Rs 279.4 crores (down 0.6% YoY) and PAT of Rs 1.3 crores, amid challenges like insurance contract renegotiations, but with positive management outlook on hospital volumes and MedTech growth.
On March 2, 2026, the stock closed at Rs 149.70, down 3.31%.
The closure pertains to franchisee units, with no specific financial quantum such as revenue contribution or cost savings disclosed in the announcement. It may impact the company's operational footprint and earnings from these sites, potentially affecting short-term revenue streams in the hospital segment. However, the persistence of OPD services mitigates complete cessation of activities. Recent Q3 FY26 results showed consolidated revenue of Rs 279.4 crores (down 0.6% YoY) and PAT of Rs 1.3 crores, amid challenges like insurance contract renegotiations, but with positive management outlook on hospital volumes and MedTech growth.
On March 2, 2026, the stock closed at Rs 149.70, down 3.31%.
Shalby informs about newspaper publication
Stock NewsSHALBY13 Feb 2026
NULL
Shalby Ltd Q3 EBITDA Declines to Rs 30.20 Crores, Margin at 11.10% YoY.
ResultSHALBY11 Feb 2026
Shalby Ltd reported Q3 EBITDA of Rs 30.20 crores, down from Rs 34.00 crores YoY, with EBITDA margin contracting to 11.10% from 12.34% YoY. This indicates a decline in profitability metrics for the quarter.
Context from detailed results shows consolidated revenue at Rs 281.1 crores, reflecting 27.4% YoY growth, driven by implant business and Delhi NCR hospital acquisition. In-patient count rose 7.9% YoY to 22,369, with ARPOB up 14.4% YoY to Rs 42,704. Standalone revenue grew 13.3% YoY to Rs 227 crores, EBITDA marginally up 0.8% to Rs 48.8 crores at 21.5% margin. Implant business revenue increased 25% YoY to Rs 26.9 crores. Net debt at group level stood at Rs 266.7 crores, with standalone net cash of Rs 66 crores.
Management highlighted consistent hospital performance across core specialties contributing 80% to revenues and 15% realized return on capital employed from hospital business on annualized basis. Shalby Academy enrolled over 1000 students. No street expectations or market reaction data available in context.
Shalby Ltd Reports Q3 Consolidated Net Profit of Rs 1.77 Crores vs YoY Loss.
ResultSHALBY11 Feb 2026
Shalby Ltd announced Q3 consolidated results, recording net profit of Rs 1.77 crores compared to a loss of Rs 1.80 crores YoY. Consolidated revenue stood at Rs 272 crores, slightly down from Rs 275 crores YoY[1].
Detailed results from ICICI Direct indicate consolidated revenue at Rs 281.1 crores, up 27.4% YoY, driven by implant business and Delhi NCR hospital acquisition. Consolidated EBITDA was Rs 39.3 crores. Standalone revenue grew 13.3% YoY to Rs 227 crores, with EBITDA at Rs 48.8 crores and margin of 21.5%. In-patient count rose 7.9% YoY to 22,369, ARPOB increased 14.4% YoY to Rs 42,704. Core specialties contributed 80% to revenues. Implant business revenue reached Rs 26.9 crores, up 25% YoY. Net debt at group level was Rs 266.7 crores, with standalone net cash of Rs 66 crores[1].
Other sources show varying figures, including revenue at Rs 285.43 crores with QoQ decline and net profit at Rs 8.92 crores QoQ from loss. Management highlighted consistent hospital performance and strategic growth initiatives[1][2].

